Publications

Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal.

Rave, N; Sharma, AK; Chapagain, RH; Nguyen, A; Pecenka, C; Shaaban, FL; Bont, LJ; CLARK, A; RSV GOLD III – Health Economics Study Group,;

2025

Journal of global health, (2025).15, 10.7189/jogh.15.04292.

Emergency Surgery Or noT for common Vascular conditions in the periods before and during COVID-19 (ESORT-V): Study Protocol.

Hinchliffe, R; JAGADEESH, A; O'NEILL, S; Wong, K; ZHU, Z; BIDULKA, P; Hutchings, A; Mouton, R; CROMWELL, D; GRIEVE, R;

2025

, London School of Hygiene & Tropical Medicine (2025). 10.17037/PUBS.04677734.

Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and markets.

Meyer-Rath, G; Jamieson, L; Mudimu, E; SNYMAN, K; Ong, JJ; Corlis, J; Warren, M; WISEMAN, V; Kripke, K; Barnabas, R; Phillips, A; Head, J; Stenberg, K; Sully, EA;

2025

Lancet (London, England), (2025).406 10515 10.1016/S0140-6736(25)01724-6.

Real world implementation of AlcoChange, a smartphone digital therapeutic to improve outcomes from alcohol-related liver disease: protocol for an individually randomised parallel group controlled trial.

Cook, A; Bamber, J; Chinnery, F; Webley, F; Dixon, E; McDonagh, L; Allen, R; Boddu, R; Gurm, H; Saffioti, F; Rajoriya, N; Sobell, L; Sobell, M; Stuart, B; Kumar, R; SADIQUE, Z; Lawrence, M; Ewings, S; Jalan, R; Mehta, G;

2025

Trials, (2025).26 1 10.1186/s13063-025-09005-3.

Clinical and cost-effectiveness of diverse posthospitalisation pathways for COVID-19: a UK evaluation using the PHOSP-COVID cohort.

BRIGGS, AH; Ibbetson, A; Walters, A; Houchen-Wolloff, L; Armstrong, N; Emerson, T; Gill, R; Hastie, C; Little, P; Overton, C; Pimm, J; Poinasamy, K; Singh, S; Walker, S; Leavy, OC; Richardson, M; Elneima, O; McAuley, H; Shikotra, A; Singapuri, A; Sereno, M; Saunders, RM; Harris, VC; Greening, NJ; Harrison, E; ... PHOSP-COVID Study Collaborative Group,

2025

BMJ open respiratory research, (2025).12 1 10.1136/bmjresp-2025-003224.

Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis.

KIM, C; SWEENEY, S; Sohn, H; KNIGHT, GM; MCQUAID, CF;

2025

PLOS global public health, (2025).5 10 10.1371/journal.pgph.0005275.

Effectiveness and cost-effectiveness of a transdiagnostic intervention targeting alcohol misuse and psychological distress for men in Ukraine: study protocol for a randomised controlled trial.

VAN DER BOOR, CF; Kachai, V; Harbar, K; Pastukhova, A; NEUMAN, M; WEISS, HA; GRECO, G; MAY, C; NADKARNI, A; ROBERTS, B; Bogdanov, S; Fuhr, DC;

2025

Trials, (2025).26 1 10.1186/s13063-025-09143-8.

Global, regional and national burden of chikungunya: force of infection mapping and spatial modelling study.

KANG, H; LIM, A; Auzenbergs, M; CLARK, A; Colón-González, FJ; Salje, H; Clapham, H; Carrera, JP; Kim, J-H; Malarski, M; López-Vergès, S; Cucunubá, ZM; Cerqueira-Silva, T; EDMUNDS, WJ; Sahastrabuddhe, S; BRADY, OJ; ABBAS, K;

2025

BMJ Global Health, (2025).10 10 10.1136/bmjgh-2024-018598.

Reforming financing of the NHS.

MAYS, N; HANSON, K;

2025

BMJ (Clinical research ed.), (2025).390, 10.1136/bmj.r1948.

Obituary: Prof. J. Patrick Vaughan, CBE, founding editor of 'Health Policy and Planning'.

GILSON, L; WISEMAN, V;

2025

Health Policy and Planning, (2025).40 8 10.1093/heapol/czaf053.